INTRODUCTION
============

Cells continuously encounter a wide variety of intrinsic and extrinsic stresses that damage the integrity of DNA ([@b39-molce-40-2-83]). Mitochondrial respiratory chain generates reactive oxygen species (ROS), which are the most prevalent intrinsic source of DNA damage. Extrinsic sources of DNA damage are ionizing radiation (IR), ultraviolet (UV), and genotoxic chemical agents, including chemotherapeutic drugs (e.g., camptothecin, doxorubicin, and etoposide). Both of the sources attack DNA and produce DNA lesions or breaks ([@b8-molce-40-2-83]). If not properly repaired, these damages are capable of blocking DNA replication and transcription, leading to mutations or genome aberrations, which consequently give rise to various human diseases, such as cancer.

To maintain genome stability against the stresses, cells operate DNA damage response (DDR) to detect DNA lesions, signal their presence, and promote their repair ([@b19-molce-40-2-83]; [@b18-molce-40-2-83]; [@b65-molce-40-2-83]). If DDR alone cannot completely handle DNA damage, cells employ an additional defense mechanism, called DNA damage tolerance (DDT) that allows DNA replication with the bypass of DNA lesions, which eventually is repaired at a later stage ([@b67-molce-40-2-83]). Both DDR and DDT are tightly controlled by post-translational protein modifications (PTMs), including phosphorylation, acetylation, methylation, poly (ADP-ribosyl)ation, and modification by ubiquitin and ubiquitin-like proteins (UBLs). Ubiquitin and UBLs are henceforth referred to as the ubiquitin family. When cells are seriously damaged by genotoxic stresses and cannot be repaired by DDR and DDT, they are then committed to kill themselves through a suicide process, called apoptosis. PTMs are also critically involved in the control of apoptotic process for selective and permanent elimination of damaged cells.

UBLs are small-size polypeptides whose three-dimensional structures are strikingly similar to that of ubiquitin, although the similarity in their amino acid sequences to ubiquitin significantly varies ([@b30-molce-40-2-83]). So far more than ten UBLs have been identified and they include ATG8, FAT10, HUB1, ISG15, NEDD8, SUMO(1--4), UFM1, and URM1 ([@b24-molce-40-2-83]). Most UBLs are conjugated to specific target proteins by a three-enzyme cascade system (E1, E2, and E3) that resembles ubiquitination. Protein modifications by ubiquitin and UBLs are reversible processes that are catalyzed by isopeptidases, called deubiquitinating enzymes (DUBs) and UBL-specific proteases (ULPs), respectively. These reversible protein modification processes play important roles in the regulation of key cellular processes, including cell proliferation, cell differentiation, and apoptosis. Furthermore, deregulation of these modification systems results in a wide variety of human diseases, including cancer, neurodegenerative disorders, and immune diseases.

Of the ubiquitin family, the roles of ubiquitin, SUMO, and NEDD8 in the control of DDR and DDT as well as of apoptosis have been extensively studied and reviewed in detail ([@b5-molce-40-2-83]; [@b7-molce-40-2-83]; [@b22-molce-40-2-83]; [@b64-molce-40-2-83]). However, relatively little is known about the function of ISG15 under DNA damage conditions. In this review, we overview the recent progress made in exploring the functional significance of ISG15 and its reversible modification of target proteins in the regulation of cellular responses to genotoxic stress and thus in their implication in human diseases, particularly cancer.

IGS15
=====

The product of interferon (IFN)-stimulated gene 15 (ISG15) is the first reported UBL ([@b17-molce-40-2-83]). This 15-kDa protein consists of two ubiquitin-like domains corresponding to the N- and C-terminal regions, which share 29% and 31% amino acid sequence identities with ubiquitin, respectively ([@b17-molce-40-2-83]; [@b26-molce-40-2-83]). Like ubiquitination, ISG15 is conjugated to target proteins by an enzymatic cascade: ISG15-activating E1 enzyme (UBE1L), ISG15-conjugating E2 enzyme (UBCH8), and ISG15 E3 ligases (e.g., HERC5 and EFP) ([@b32-molce-40-2-83]; [@b74-molce-40-2-83]; [@b78-molce-40-2-83]; [@b79-molce-40-2-83]; [@b82-molce-40-2-83]). This conjugation process can be reversed by the major deISGylating enzyme UBP43, also called USP18 ([@b47-molce-40-2-83]). ISG15 is not present in *Drosophila*, *Caenorhabditis*, and *Saccharomyces*, indicating that its functions are restricted to higher animals.

ISG15 is robustly induced by type-I IFNs, lipopolysaccharide, and viral infection ([@b10-molce-40-2-83]; [@b31-molce-40-2-83]; [@b42-molce-40-2-83]; [@b49-molce-40-2-83]). One of the major components of the innate immune response is the activation of type I IFN signaling pathways ([@b60-molce-40-2-83]; [@b72-molce-40-2-83]). Proteomic analysis has revealed that regulatory proteins involved in antiviral IFN signaling pathways, such as RIG-I, IRF3, MDA-5, STAT1, JAK1, and filamin B, serve as targets for ISG15 modification ([@b1-molce-40-2-83]; [@b25-molce-40-2-83]; [@b33-molce-40-2-83]; [@b80-molce-40-2-83]). Moreover, ISG15 and its conjugation to target proteins have been implicated in impairment of viral replication in vivo ([@b45-molce-40-2-83]; [@b48-molce-40-2-83]; [@b56-molce-40-2-83]). Conversely, certain viruses induce their own proteins that can block the expression of ISG15 (e.g., NS3/4A) or generation of ISG15-conjugated proteins (e.g., NS1B) or promote deconjugation of ISG15 from its target proteins (i.e., deISGylating enzymes, including OTU, PLpro, and viral E3 protein), thus abrogating the antiviral immune responses ([@b12-molce-40-2-83]; [@b40-molce-40-2-83]; [@b44-molce-40-2-83]; [@b61-molce-40-2-83]; [@b78-molce-40-2-83]; [@b81-molce-40-2-83]). In addition, mice lacking ISG15 or UBE1L exhibit increased susceptibility to infection by certain viruses, including influenza B virus, herpes simplex virus, and/or Sindbis virus ([@b14-molce-40-2-83]; [@b34-molce-40-2-83]; [@b36-molce-40-2-83]), further indicating the role of ISG15 and its conjugation of target proteins in antiviral responses.

ISG15 is also induced by genotoxic stresses. UV was first shown to increase the level of ISG15 transcripts by about four fold in human skin fibroblasts ([@b13-molce-40-2-83]). Camptothecin, an inhibitor of topoisomerase I, also increases the level of ISG15 mRNA and this increase requires protein synthesis and a functional p53 protein ([@b41-molce-40-2-83]). Significantly, camptothecin-mediated induction of ISG15 is independent of IFN signaling pathway and ISG15 conjugates formed by the drug treatment are different from those generated by type I IFNs, indicating that different signals induce ISGylation of different target proteins ([@b59-molce-40-2-83]). Moreover, the *ISG15* gene has a putative p53-responsive element (*p53RE*) for its induction in addition to IFN-sensitive response element (*ISRE*) ([@b62-molce-40-2-83]). Collectively, these findings suggest that ISG15 and its conjugated proteins participate in the control of cellular responses to DNA damage.

ISG15 MODIFICATION OF P53
=========================

The p53 tumor suppressor coordinates cellular responses to DNA damage as well as to other stresses, such as abnormal oncogene activation, telomere erosion, and hypoxia ([@b15-molce-40-2-83]; [@b63-molce-40-2-83]). Under normal conditions, the level of p53 protein is kept low by several E3 ligases-mediated ubiquitination. Among them, MDM2 is the major ubiquitin E3 ligase that leads to degradation of p53 by proteasome. Interestingly, the expression of MDM2 is induced by p53, thus forming a negative feedback loop for down-regulation of p53 ([@b2-molce-40-2-83]; [@b57-molce-40-2-83]; [@b75-molce-40-2-83]). Under stressed conditions, however, the interaction of p53 with MDM2 and other negative regulators is disrupted by phosphorylation and acetylation, leading to stabilization and activation of p53. The activated p53 then binds to *p53REs* for transcriptional activation of its target genes (e.g., *BAX, CDKN1, and PUMA*) that mediate cell cycle arrest and/or apoptosis, depending on the degree of stresses ([@b9-molce-40-2-83]; [@b53-molce-40-2-83]; [@b55-molce-40-2-83]).

Recently, we have shown that *p53RE* is present not only in the *ISG15* gene but also in the promoter regions of the genes encoding UBE1L (E1), UBCH8 (E2), and EFP (E3), all of which are henceforth referred to as the ISG15-conjugating system ([@b59-molce-40-2-83]). Accordingly, treatment with DNA-damaging agents, such as UV, camptothecin, and doxorubicin, markedly induces both the mRNA and protein levels of UBE1L, UBCH8, and EFP in *p53*^+/+^ cells, but not in *p53*^−/−^ cells, and this induction can be abrogated by caffeine, an inhibitor of ATM/ATR kinases ([@b68-molce-40-2-83]), which phosphorylate Chk1 and p53 for the expression of p53. In addition, DNA damage-mediated induction of the ISG15-conjugating system is independent of type I IFNs, indicating that p53 alone can positively regulate the expression of ISG15 and its conjugation system.

DNA-damaging agents are capable of inducing ISGylation of p53 as well as overexpression of the ISG15-conjugating system ([@b59-molce-40-2-83]). Lys291 and Lys292 serve as the major ISG15-acceptor sites in p53. Of two known ISG15 E3 enzymes, EFP, but not HERC5, acts as a p53-specific ligase. HERC5 lacks *p53RE*, consistently with the finding that the ligase is not induced under DNA-damaging conditions. Intriguingly, ISGylation of p53 promotes its transcriptional activity and in turn in the expression of its downstream target genes, including *CDKN1, MDM2*, *BAX*, and *ISG15*, as well as of its own gene. This increase of the p53 activity is mediated by the ability of ISG15-conjugated p53 to promote its phosphorylation and acetylation and thereby to increase its affinity toward *p53RE*. Furthermore, p53 ISGylation suppresses cell growth and tumor development *in vivo*. Knockdown of ISG15 or any of the ISG15-conjugating system or Lys-to-Arg mutations of the ISG15 acceptor sites in p53 strongly attenuates DNA damage-induced p53 activity and in turn its tumor suppressive function ([@b59-molce-40-2-83]). Thus, cells appear to operate a novel feedback circuit between p53 and the ISG15-conjugating system for positive control of p53 tumor suppressive function under genotoxic stress conditions.

ISG15 MODIFICATION OF ΔNP63α
============================

The p53 protein family consists of p53, p63, and p73. Different isotypes can be generated from their genes due to the presence of different promoters ([@b38-molce-40-2-83]). For example, the *p63* gene generates two types of transcripts: one for p63 having an N-terminal transactivation domain (TA) and the other for p63 lacking TA domain (ΔN). In addition, both TA and ΔN transcripts are differentially spliced at their 3′ ends to generate the p63 proteins with unique C-termini, termed α, β, γ, δ, and ɛ ([@b51-molce-40-2-83]). Similar to p53, TAp63 isotypes can activate transcription from p53-responsive genes, which induce cell cycle arrest and apoptosis, thus also functioning as tumor suppressors ([@b11-molce-40-2-83]; [@b71-molce-40-2-83]).

Of the p63α isotypes, ΔNp63α has the transactivation inhibitory domain (TI) but lacks the TA domain and therefore can dominant-negatively suppress transcriptional activation of the p53 family member by binding to their TA domains ([@b16-molce-40-2-83]; [@b69-molce-40-2-83]; [@b76-molce-40-2-83]), contributing to its anti-apoptotic, mitogenic, and tumorigenic functions. ΔNp63α is the most abundant p63 isotype in many proliferating epithelial cells, such as MCF10A ([@b6-molce-40-2-83]; [@b52-molce-40-2-83]; [@b77-molce-40-2-83]). Significantly, its expression is frequently amplified in human epithelial cancers, such as squamous cell carcinomas, advanced cervical carcinomas, and human breast carcinomas, supporting its role in tumorigenesis ([@b20-molce-40-2-83]; [@b37-molce-40-2-83]).

DNA-damaging agents, such as camptothecin and doxo-rubicin, induce ISGylation of ΔNp63α in MCF10A and various epithelial cancer cell lines, including HNSCC013, HCC1937, and FaDu ([@b27-molce-40-2-83]). Lys139 and Lys324 serve as the ISGylation sites in ΔNp63α. Upon exposure to the DNA-damaging agents, caspase-2 is activated, although with an unknown mechanism(s), and cleaves off the TI domain from ISGylated ΔNp63α, but not from its unmodified form, suggesting that ISG15 molecules conjugated toΔNp63α act as molecular scaffolds for recruiting activated caspase-2. Asp452, Asp469, and Asp489 are the cleavage sites in ΔNp63α. The cleaved TI domain is exported to the cytoplasm from the nucleus, thus losing its ability to bind the TA domain and inhibit the transcriptional activity of TA domain-containing p53 family members in the nucleus. Under the same stress conditions, TAp63α, is also ISGylated and cleaved by caspase-2 and its TI domain is released to the cytoplasm, thus yielding a transcriptionally active form of TAp63α.

Furthermore, ISGylation of ΔNp63α abrogates its ability to induce cell growth and tumor formation ([@b27-molce-40-2-83]). Knockdown of ISG15, Lys-to-Arg mutations of ISGylation sites, or Asp-to-Ala mutations of cleavage sites by caspase-2 strongly potentiate the ability of ΔNp63α to promote anchorage-independent cell growth and tumor development *in vivo*. These findings indicate that ISG15 and its conjugation to ΔNp63α play critical roles in suppression of tumor-igenesis particularly in epithelial cancer cells under genotoxic stress conditions. As both camptothecin and doxorubicin are well-known anticancer drugs, these findings also provide a molecular basis for chemotherapeutic drugs against ΔNp63α-mediated cancers.

Notably, cisplatin, unlike camptothecin and doxorubicin, is unable to induce the ISG15-congugating system and ΔNp63α ISGylation, although it also acts as a DNA-damaging agent as well as an anticancer drug. However, cisplatin is capable of inducing cAbl-mediated phosphorylation of TAp73, which causes the dissociation of TAp73 from ΔNp63α and in turn the promotion of its transcriptional activity to induce apoptosis ([@b37-molce-40-2-83]). Thus, cisplatin, like camptothecin and doxorubicin, impairs the dominant-negative function ofΔNp63α toward TA domain-containing p53 family members, although it does not exhibit any effect on ISGylation and caspase-2-mediated cleavage of ΔNp63α, unlike camptothecin and doxorubicin.

ISG15 MODIFICATION OF PCNA
==========================

The sliding clamp proliferating cell nuclear antigen (PCNA) serves as a processivity factor as well as a platform for recruiting necessary components for DNA replication. Moreover, PCNA is critically involved in DNA lesion bypass by acting as a scaffold that recruits essential components for DDT ([@b54-molce-40-2-83]), indicating that PCNA plays an additional key role in the maintenance of genome stability and cell survival under DNA damage conditions.

When replicating cells encounter DNA damage, PCNA undergoes numerous PTMs, such as ubiquitination and sumoylation ([@b3-molce-40-2-83]; [@b23-molce-40-2-83]; [@b46-molce-40-2-83]; [@b73-molce-40-2-83]). UV induces mono-ubiquitination of a highly conserved Lys164 residue in PCNA by the ubiquitin E3 ligase RAD6-RAD18 complex ([@b21-molce-40-2-83]). This PCNA ubiquitination triggers the replacement of replicative DNA polymerases, such as Polη, by damage-tolerant Y family of DNA polymerases, including Polδ, for translesion DNA synthesis (TLS) ([@b4-molce-40-2-83]; [@b28-molce-40-2-83]; [@b29-molce-40-2-83]; [@b35-molce-40-2-83]; [@b70-molce-40-2-83]). TLS polymerases bypass DNA lesion and therefore DNA replication can proceed without the need of removal of the damage and the risk of fork collapse ([@b66-molce-40-2-83]; [@b67-molce-40-2-83]). However, TLS polymerases lack proofreading activity and frequently incorporate incorrect nucleotides, therefore are potentially mutagenic ([@b43-molce-40-2-83]; [@b50-molce-40-2-83]; [@b66-molce-40-2-83]; [@b67-molce-40-2-83]). Thus, error-prone TLS polymerases have to be released from PCNA after DNA lesion bypass for preventing excessive mutagenesis.

Upon DNA damage by UV, PCNA consisting of three identical subunits is first mono-ubiquitinated (at Lys164) for recruitment of Polη and thus for initiation of TLS, as previously documented in detail ([@b4-molce-40-2-83]; [@b28-molce-40-2-83]; [@b29-molce-40-2-83]; [@b35-molce-40-2-83]; [@b70-molce-40-2-83]). After DNA lesion bypass, the ISG15 E3 ligase EFP, but not HERC5, is tethered to mono-ubiquitinated PCNA, and generates mono-ISGylated PCNA (at Lys168), leading to formation of PCNA conjugated with both ubiquitin and ISG15 in different subunits ([@b58-molce-40-2-83]). ISGylated PCNA then recruits PCNA-interacting peptide (PIP) motif-containing USP10 for deubiquitination of PCNA, which causes the release of Polη from PCNA for termination of TLS. EFP conjugates an additional ISG15 to PCNA at Lys164, thus forming PCNA ligated with two ISG15 molecules in the same subunit, likely for preventing mono-ubiquitination at Lys164 and re-recruitment of Polη. Finally, UBP43 is induced at a later period and cleaves off ISG15 molecules from PCNA for reloading of replicative DNA polymerases and resuming of DNA replication. For this sequential modification of PCNA (i.e., mono-ubiquitination, ISGylation, deubiquitination, ISGylation, and deISGyation), expression of the proteins responsible for the processes (i.e., RAD6-RAD18, ISG15 and EFP, USP10, and UBP43) is induced in order after UV irradiation, although it remains mysterious how the timely expression of each component of PCNA modifications is regulated. Moreover, knockdown of any of ISG15, EFP, and USP10 as well as Lys-to-Arg mutations of the ISGylation sites in PCNA lead to a dramatic increase in UV-mediated mutation frequency with a decrease in cell survival ([@b58-molce-40-2-83]). Thus, PCNA ISGylation appears to play a crucial role in termination of error-prone TLS after DNA lesion bypass for escaping from excessive mutagenesis and thereby maintaining genome stability.

CONCLUSION
==========

Type I IFNs and viral and microbial infections induce the expression of ISG15. Further, its conjugation to target proteins plays essential roles in innate immune responses, such as anti-viral and anti-microbial functions. Recent studies indicate that ISG15 and its conjugating system, including UBE1L (E1), UBCH8 (E2), and EFP (E3), are also induced under DNA damage conditions and this induction is positively regulated by p53. Moreover, p53-mediated increase in the levels of ISG15 and its conjugating system leads to ISGylation ofΔNp63α and PCNA as well as itself. ISGylation of p53 forms a positive feedback loop for its transcriptional activation, resulting in the expression of p53-downstream target genes for cell cycle arrest and apoptosis under DNA damage conditions. On the other hand, DNA damage-induced ISGylation of ΔNp63α negatively regulates its anti-apoptotic and mitogenic functions by caspase-2-mediated destabilization. In addition, reversible PCNA ISGylation relays a signaling pathway to turn off error-prone TLS after DNA lesion bypass for suppressing UV-induced mutagenesis as well as for resuming normal DNA replication. Thus, it appears clear that ISG15 and its conjugation to target proteins play a crucial function in the control of cellular responses to genotoxic stresses and in turn in suppression of DNA damage-mediated tumor-igenesis.
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![Positive feedback regulation of p53 transactivity by ISG15 modification\
When cells are insulted by DNA-damaging agents, p53 is phosphorylated and acetylated, such as by Chk1 and p300, respectively, resulting in its dissociation from MDM2 and stabilization. The stabilized p53 is then conjugated by ISG15 and this modification increases phosphorylation (pink circle: P) and acetylation (blue circle: A) of p53 and in turn in its ability to bind *p53RE* for the expression of ISG15, its conjugating system (E1--3), and other targets, including p21 and BAX, as well as itself. This increased expression of ISG15 and E1--3 further accelerates p53 ISGylation and subsequent processes for suppression of cell growth and tumor development by forming a positive feedback loop. When this loop is no longer necessary, UBP43 is induced and deISGylates p53 for destabilization.](molce-40-2-83f1){#f1-molce-40-2-83}

![Ablation of oncogenic function of ΔNp63α by ISG15 modification\
DNA damage induces ISGylation of ΔNp63α, which leads to caspase-2-mediated cleavage and release of the C-terminal TI domain. The cleaved ΔNp63α no longer can inhibit the transcriptional activities of the p53 family members, thus allowing their apoptotic functions.](molce-40-2-83f2){#f2-molce-40-2-83}

![Termination of TLS by ISGylation of PCNA\
Under normal conditions, PCNA serves as processivity factor for replicative DNA synthesis. Upon DNA damage by UV, PCNA is mono-ubiquitinated by the RAD6/RAD18 E3 complex for tethering Polη for TLS. After bypassing DNA lesions, EFP generates ISGylated PCNA for recruiting USP10 and thereby for elimination of ubiquitin and release of Polη from PCNA. EFP then produces doubly ISGylated PCNA, likely for blocking unnecessary mono-ubiquitination of PCNA. Finally, UBP43 removes both ISG15 molecules for reloading replicative DNA polymerases and thereby for resuming normal DNA replication.](molce-40-2-83f3){#f3-molce-40-2-83}
